Investors & Media
Corporate Profile
Aileron Therapeutics is focused on transforming the experience of chemotherapy for cancer patients, enabling them to fight cancer without the fear or burden of chemotherapy-induced side effects. We are advancing ALRN-6924, our first-in-class dual MDM2/MDMX inhibitor currently in clinical development, to provide a single medicine to protect multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells.
More >>Stock
(Common Stock) | |
---|---|
- | |
Exchange | |
Volume | |
Today's Open | |
Previous Close | |
Data as of |
Data Provided by Refinitiv. Minimum 15 minutes delayed.